Search results
Showing 1901 to 1950 of 2053 results for work
First-ever NHS treatment approved for advanced Hodgkin lymphoma
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
Changes approved to the routing criteria for highly specialised technologies
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
Harnessing expertise to improve patient access to innovative health technologies
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
New option for adult leukaemia patients as we recommend treatment
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
Tributes paid following the death of founding NICE chairman Professor Sir Mike Rawlins
Founding chairman led NICE from 1999 to 2013, through its early years to its current position as a world leader in health and social care guidance and medicine evaluation.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
NICE chronic lung disease treatment decision could benefit 5,200 people
NICE broadens nintedanib recommendation on chronic lung disease treatment.
Improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE.
Dr Sam Roberts has been outlining the changes underway at NICE to meet the challenges of a rapidly evolving health technology sector and patient expectations
Decision aid to guide discussions on sleeping pill prescriptions
A patient decision aid on medicines associated with dependence or withdrawal symptoms has been published
NICE recommends 8 digitally enabled therapies to treat depression and anxiety
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.
Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety or low mood have been recommended for use in the NHS.
Draft guidance for the potential of new targeted treatment for type of advanced breast cancer
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.
The first in a new class of treatment to be recommended by NICE for treating acute migraine will soon be available on the NHS to around 13,000 people.
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.
New Chief Medical Officer, Chief People Officer and Director of Implementation and Partnerships appointed by NICE.
Adults with depression who want to quit antidepressants should be given support
Adults with depression who want to stop taking antidepressants should have the dose of their medication reduced in stages to reduce the likelihood and severity of withdrawal symptoms, NICE has said.
New treatment for advanced breast cancer recommended by NICE
Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
Public consultation on our new approach to prioritising guidance now open
The consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.
NICE's Early Value Assessment for Medtech: panning for nuggets of innovation gold
Early Value Assessment for Medtech and how it will offer a rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money.
NICE has launched a free learning course that provides an introduction to health technology assessment (HTA).
Angela sets out to understand some of the challenges, benefits and considerations of setting up and running a virtual ward, from the perspective of teams on the front lines.
Working in partnership to harness the potential of digital technology
Nicola Bent talks about NICE and the AHSN Network’s important ambition to address market access challenges for digital innovation as part of the collaboration agreement.
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.
As we launch an early version of the online service, mapping out the regulatory and health technology assessment pathway, Ciara Cook invites future users to help shape this exciting new initiative.
A refreshed Evidence Standards Framework for Digital Health Technologies
Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system faster.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.
How is NICE supporting digital health technology developers?
Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.
Using our guidance and resources in continuing professional development (CPD)
Registered social workers must demonstrate the use of evidence and research to inform their practice in order to meet professional standards. This is echoed in Social Work England’s continuing professional development (CPD) standards.
Pilar Pinilla-Dominguez reveals how NICE, through its international collaborations and partnerships, aims to contribute to improvements in health and care outcomes across the world, bringing learnings and benefits back to NICE, the NHS and the wider UK health and care system.
NICE calls for further research into the treatment of chronic lipoedema
NICE has today issued interventional procedures guidance on the use of liposuction for the treatment of chronic lipoedema.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.
Risdiplam not recommend for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.
More than 700 people set to benefit from new treatment option for advanced lymphoma.
NICE recommends innovative technology for people with breast cancer
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread.
Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.
New guidance aims to achieve fairer outcomes for looked-after children and young people
Looked after children and young people should be considered ‘one of their own’ by carers, to help them to reach their full potential, new NICE draft guidelines say.
New LSE master's degree in Evaluation of Health Care Interventions and Outcomes
NICE is collaborating with the London School of Economics and Political Science (LSE) to develop an executive master’s degree in health care decision-making.